Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 18/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 10/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.81 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.81 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.81 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.81 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.81 |
| ▸ | PI4KA | P42356 | 1/20 | 0.81 |
| ▸ | PIK3R4 | Q99570 | 1/20 | 0.81 |
| ▸ | PIP5K1A | Q99755 | 1/20 | 0.81 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.47 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.47 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956997 | 0.92 | PIK3C3 (1.00) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957247 | 0.91 | PIK3C3 (0.83) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957785 | 0.91 | PIK3C3 (0.83) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL29394375 | 0.90 | PIK3C3 (1.00) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957245 | 0.90 | PIK3C3 (1.00) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957195 | 0.88 | PIK3C3 (0.79) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9956230 | 0.88 | PIK3C3 (0.79) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957794 | 0.87 | PIK3C3 (0.77) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL16390643 | 0.87 | PIK3C3 (0.80) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB | |
| SCHEMBL9957031 | 0.85 | PIK3C3 (0.74) | PIK3C3PIK3CDPIK3CAPIK3CGPI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| WO-2020008046-A1 | BIOMARKER | SPRINT BIOSCIENCE AB (SE) | 2020-01-09 | — | — | WO | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| US-20230293521-A1 | METHODS FOR SCREENING NOVEL CORONAVIRUS ANTIVIRALS AND METHODS OF USING ANTIVIRALS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-21 | — | — | US | disclosed |
| US-20230293521-A1 | METHODS FOR SCREENING NOVEL CORONAVIRUS ANTIVIRALS AND METHODS OF USING ANTIVIRALS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-21 | — | — | US | disclosed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | disclosed |
| WO-2021152467-A1 | COMBINATIONS COMPRISING BH3-MIMETIC COMPOUNDS AND INHIBITORS OF EARLY STAGES OF AUTOPHAGY FOR USE IN THE TREATMENT OF NON-HODGKIN'S B-CELL LYMPHOMAS AND LYMPHOID AND/OR MYELOID LEUKEMIAS | UNIVERSITA' DEGLI STUDI DI PADOVA (IT) | 2021-08-05 | — | — | WO | disclosed |
| WO-2020008046-A1 | BIOMARKER | SPRINT BIOSCIENCE AB (SE) | 2020-01-09 | — | — | WO | disclosed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | disclosed |
| EP-2655340-B1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-8901147-B2 | Bi-heteroaryl compounds as Vps34 inhibitors | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2014-06-05 | — | — | US | disclosed |
| EP-2655340-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | Novartis AG (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085815-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085815-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | NOVARTIS AG (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293521-A1 | METHODS FOR SCREENING NOVEL CORONAVIRUS ANTIVIRALS AND METHODS OF USING ANTIVIRALS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | SARS1, ACE, ACE2 | PIK3C3 2746/4885PIK3CD 2975/4885PIK3CA 3376/4885 |
| US-20140155402-A1 | BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS | VPS35, VPS26B, VPS26A | PIK3C3 210/4885PIK3CD 39/4885PIK3CA 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.